Last reviewed · How we verify

NCT06275633

Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD

Completed NA Last updated 23 February 2024
What this trial tests

NA trial testing Levodopa in Parkinson Disease in 68 participants. Completed in 30 July 2023.

Timeline
19 March 2019
Primary endpoint
3 December 2021
30 July 2023

Quick facts

Lead sponsorUniversity Hospital Bispebjerg and Frederiksberg
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment68
Start date19 March 2019
Primary completion3 December 2021
Estimated completion30 July 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Bispebjerg and Frederiksberg

Who can join

Adults 18 to 90, any sex, with Parkinson Disease or Medication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this project, patients with Parkinson's Disease (PD) will be characterized by measuring cognitive and motor function and relation to effect of Levodopa. Participants will be patients with Parkinson's Disease and healthy controls. It will be investigated if there is a difference between patients with a good measured Levodopa response and with a poor measured response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Levodopa

Trials testing the same drug.

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Hospital Bispebjerg and Frederiksberg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06275633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing